This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- PZ-128
- DrugBank Accession Number
- DB11839
- Background
PZ-128 has been used in trials studying the prevention and treatment of Heart Diseases, Coronary Disease, Arteriosclerosis, Vascular Diseases, and Myocardial Ischemia, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for PZ-128 (DB11839)
- Weight
- Average: 1086.479
Monoisotopic: 1085.76887182 - Chemical Formula
- C55H99N13O9
- Synonyms
- Not Available
- External IDs
- PZ 128
- PZ-128
- PZ128
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Oligopeptides
- Alternative Parents
- Phenylalanine and derivatives / Leucine and derivatives / N-acyl-alpha amino acids and derivatives / Serine and derivatives / Alpha amino acid amides / Alanine and derivatives / Amphetamines and derivatives / N-acyl amines / Secondary carboxylic acid amides / Guanidines show 9 more
- Substituents
- Alanine or derivatives / Alcohol / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-oligopeptide / Amine / Amino acid or derivatives / Amphetamine or derivatives / Aromatic homomonocyclic compound / Benzenoid show 27 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- IYT6MP4NS9
- CAS number
- 371131-16-7
- InChI Key
- VZRIKWNVDCTBTF-BKGFHLQYSA-N
- InChI
- InChI=1S/C55H99N13O9/c1-5-6-7-8-9-10-11-12-13-14-15-16-20-31-47(70)63-41(28-21-23-32-56)51(74)64-42(29-22-24-33-57)52(75)68-46(37-69)54(77)65-43(30-25-34-61-55(59)60)50(73)62-39(4)49(72)67-45(35-38(2)3)53(76)66-44(48(58)71)36-40-26-18-17-19-27-40/h17-19,26-27,38-39,41-46,69H,5-16,20-25,28-37,56-57H2,1-4H3,(H2,58,71)(H,62,73)(H,63,70)(H,64,74)(H,65,77)(H,66,76)(H,67,72)(H,68,75)(H4,59,60,61)/t39-,41-,42-,43-,44-,45-,46-/m0/s1
- IUPAC Name
- N-[(1S)-5-amino-1-{[(1S)-5-amino-1-{[(1S)-1-{[(1S)-4-carbamimidamido-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}-3-methylbutyl]carbamoyl}ethyl]carbamoyl}butyl]carbamoyl}-2-hydroxyethyl]carbamoyl}pentyl]carbamoyl}pentyl]hexadecanamide
- SMILES
- CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Prevention Acute Coronary Syndrome (ACS) / Arterial Occlusive Diseases / Arteriosclerosis / Cardiovascular Disease (CVD) / Coronary Artery Disease (CAD) / Coronary Heart Disease (CHD) / Myocardial Ischemia / Vascular Diseases 1 1 Completed Treatment Coronary Artery Disease Risk Factors Multiple / Vascular Diseases 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00282 mg/mL ALOGPS logP 2.78 ALOGPS logP 1.73 Chemaxon logS -5.6 ALOGPS pKa (Strongest Acidic) 11.51 Chemaxon pKa (Strongest Basic) 11.9 Chemaxon Physiological Charge 3 Chemaxon Hydrogen Acceptor Count 14 Chemaxon Hydrogen Donor Count 14 Chemaxon Polar Surface Area 380.96 Å2 Chemaxon Rotatable Bond Count 45 Chemaxon Refractivity 307.87 m3·mol-1 Chemaxon Polarizability 124.63 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 338.5696 predictedDeepCCS 1.0 (2019) [M+H]+ 340.2933 predictedDeepCCS 1.0 (2019) [M+Na]+ 346.4716 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 20:52 / Updated at June 12, 2020 16:53